MAP2K1 and colorectal carcinoma: Ralimetinib (the p38α kinase inhibitor) made the CRC-SCs from patients more sensitive to chemotherapy, and the combination of ralimetinib with trametinib (the MEK1 inhibitor) showed a synthetic lethality effect, suggesting that p38α targeting in CRC-SCs may be a novel CRC treatment strategy for CRC [107].